Two Indian pharma companies can report the same revenue and the same margin and be almost unrelated businesses. One earns most of its money prescribing brands to Indian doctors through a sales force of thousands; the other sells unbranded pills to American pharmacy chains from four factories in Gujarat and Telangana. The first worries about price control and doctors; the second worries about competitors’ filings and an inspector’s visit. Before any ratio, split the company.
A mithai shop has a front counter where regulars buy its famous brand of sweets, a wholesale counter supplying hotels in another city at thin margins under hard bargaining, and a back room that makes khoya for other shops. A bad month for one counter says little about the others — and if the food inspector shuts the kitchen, all three stop at once.
An Indian pharma company is usually the same three counters: branded formulations in India, generics exported to the US and other markets, and bulk drug ingredients or contract manufacturing for others. Each is analysed on its own terms. And the kitchen matters above all: every export depends on factories passing foreign inspections.
The India business: brands, doctors and price control
Indian pharma is a market of branded generics — off-patent molecules sold under company brand names, promoted to doctors by medical representatives. Growth comes from volume, new launches and price. The healthiest franchises lean towards chronic therapies — heart, diabetes, the nervous system — where patients take medicine for years, rather than acute ones such as anti-infectives, which are seasonal.
- Growth versus the market. Industry trackers publish monthly sales for the Indian pharmaceutical market; companies compare their own growth with it. Growing slower than the market is losing share.
- Price control. Medicines on the National List of Essential Medicines are scheduled and have ceiling prices set by the NPPA under the Drugs (Prices Control) Order, 2013, revised each year with the wholesale price index. Others may raise prices by up to 10% a year. A large NLEM share limits pricing.
- Sales force productivity. Revenue per medical representative. Hiring many representatives ahead of launches raises cost first and revenue later.
The US business: approvals, competitors and price erosion
To sell a generic in the US, a company files an ANDA — an abbreviated new drug application — proving its product matches the original. Once approved, it competes on price with every other approved maker. A handful of large purchasers buy for most of the US pharmacy market, so each new competitor on a molecule pushes prices down. A product with two or three makers can hold its price; one with ten becomes a commodity.
The exceptions are where the money is. A company that files a Paragraph IV challenge — arguing the brand’s patent is invalid or not infringed — and is first to file can earn 180 days of exclusivity, during which other generics cannot launch. Complex generics — injectables, inhalers, patches, biosimilars — have few competitors because they are hard to make. Both produce years of unusually high profit that then fall away, so check how much of current profit rests on one or two such products and when their exclusivity or advantage ends.
The factory: inspections, letters and alerts
| Stage | What happens | What it means for the company |
|---|---|---|
| Inspection | US FDA investigators visit a plant, announced or not | Routine; every US-supplying site is inspected periodically |
| Form 483 | A list of observations handed over at the end | Not final. A few minor points are common; many serious ones, especially on data integrity, are a warning sign |
| Classification: NAI / VAI / OAI | No action, voluntary action, or official action indicated | NAI and VAI are clean or manageable. OAI means enforcement is likely and new approvals from that site are usually held |
| Warning letter | A formal letter citing significant violations | Approvals from the plant stall; remediation takes time and money |
| Import alert | Products from the plant can be detained at the US border | Exports from that plant to the US effectively stop until the FDA is satisfied |
Research spending, and what it buys
Research and development is usually shown as a share of sales. Generic companies spend on developing and filing new products; a few also fund novel drugs or specialty brands with long, uncertain timelines. Check whether R&D is expensed or partly capitalised — capitalising it raises current profit — and whether spending actually produces filings and approvals over time. A steady flow of approvals is the evidence that the money is working.
A pharma company’s main US-supplying plant receives an OAI classification after inspection. The most direct near-term effect is usually:
Pharma company asal mein teen business hai — India mein brand (doctor ke through), US mein generic dawai, aur API/contract manufacturing. India mein NLEM wali dawaiyon ka daam NPPA fix karta hai; baaki ka saal mein max 10% badh sakta. US mein har naya competitor aate hi generic ka daam girta — isliye naye approvals chahiye. Sabse bada risk factory: USFDA ka Form 483 final nahi, par OAI, warning letter ya import alert aaya toh us plant se US export ruk sakta. Dekho kaunsi plant se kitni US kamai aati hai.
- Split a pharma company into India brands, US and other generics, and API or contract manufacturing — each has its own drivers.
- India: branded generics, chronic versus acute mix, growth versus the market, and price control on NLEM medicines.
- US generics erode as competitors arrive; growth needs a steady flow of new, preferably complex, approvals.
- First-to-file Para IV exclusivity and limited-competition products create profits that fade — know when.
- A Form 483 is not final; OAI, warning letters and import alerts are. Map US revenue to each plant.
Mark it done to track your progress through the curriculum.
Common questions
Short, direct answers to what people ask about this topic.
- what is form 483 in pharma
- A Form 483 is the list of observations a US FDA investigator hands to a factory at the end of an inspection, recording conditions that may breach manufacturing rules. It is not a final finding: the company replies, and the FDA later classifies the inspection as NAI (no action indicated), VAI (voluntary action indicated) or OAI (official action indicated). A few minor observations are common; many serious ones, especially on data integrity, raise the risk of a warning letter.
- what is an import alert by USFDA
- An import alert allows US border officials to detain products from a named factory without examining them, which in practice stops that plant from exporting to the US. It usually follows serious compliance failures and can last years, until the FDA is satisfied after re-inspection. For an Indian pharma company, an import alert on a major US-supplying plant can remove a large part of US revenue and hold up new approvals linked to that site.
- para IV filing meaning in pharma
- A Paragraph IV certification is a generic applicant’s claim, in its ANDA, that a brand’s patent is invalid or would not be infringed by the generic. The first company to file one can be rewarded with 180 days of marketing exclusivity during which other generics cannot launch, when prices stay far higher than in an open market. It usually triggers patent litigation, so the outcome, timing and value are uncertain until the case or settlement is resolved.
- how does drug price control work in India
- Medicines on the National List of Essential Medicines (NLEM) are scheduled formulations whose ceiling prices are fixed by the National Pharmaceutical Pricing Authority under the Drugs (Prices Control) Order, 2013, and revised annually in line with the wholesale price index. For medicines not under price control, companies may raise the maximum retail price by no more than ten per cent in a year. A company with a large share of sales under price control has less pricing freedom at home.